|  |  |  |  |
| --- | --- | --- | --- |
| **eTable 7** Univariable models for disease worsening at two-year follow-up in RRMS patients on highly active treatment, excluding patients treated with fingolimod, at baseline (n=23). | | | |
|  | **OR** | **95 % CI** | **p-value** |
| sNfL ≥ 75 th\* | 1.435 | 0.221-9.340 | 0.705 |
| sNfL (pg/mL, continuous) | 1.253 | 0.899-1.747 | 0.183 |
| Age | 0.902 | 0.785-1.035 | 0.142 |
| Total CD3+ | 1.001 | 0.936-1.070 | 0.976 |
| CD3+CD4+ | 1.033 | 0.944-1.130 | 0.478 |
| CD4+CD25+CD127- (CD4+T-reg) | 1.292 | 0.690-2.420 | 0.423 |
| CD3+CD8+ | 0.944 | 0.818-1.089 | 0.432 |
| CD3+CD8+CD28-CD127- (CD8+T-reg) | 0.983 | 0.918-1.054 | 0.635 |
| CD3+CD4+CCR6-CD161-CXCR3+ (Th1) | 1.006 | 0.864-1.170 | 0.943 |
| CD3+CD4+CCR6+CD161+CXCR3-CCR4+ (Th17) | 0.583 | 0.099-3.423 | 0.550 |
| CD3+CD4+CCR6+CD161+CxCR3highCCR4low (Th1/Th17) | 0.821 | 0.280-2.409 | 0.719 |
| Total CD19+ | 1.036 | 0.939-1.143 | 0.485 |
| CD19+CD24highCD38low (B-memory) | 935 | 0.820-1.068 | 0.327 |
| CD19+CD24lowCD38low (B-mature) | 1.024 | 0.969-1.081 | 0.405 |
| CD19+CD24highCD38high (B-reg) | 0.984 | 0.889-1.088 | 0.748 |
| CD19+CD24-CD38high (plasma B-cells) | 0.890 | 0.467-1.697 | 0.724 |
| CD16+CD56low (CD56 dim) | **0.872** | **0.762-0.999** | **0.048** |
| CD16+CD56high (CD56 brigh) | 0.972 | 0.804-1.175 | 0.769 |
| Abbreviations: RRMS = relapsing remitting MS; highly active treatment = natalizumab, alemtuzumab, rituximab and ocrelizumab. sNfL= serum neurofilament light chain; disease worsening = ≥ 3 new cerebral MRI lesions and/or confirmed Expanded Disability Status Score (EDSS) progression and/or evidence of a new clinical relapse. Results are presented with odds ratio (OR), 95% confidence interval (CI) and p-value. In bold are shown significant p-values, and the corresponding OR. The analyses were adjusted for age and gender. \*Cut off 75 th percentile: 20-29 years ≥ 4.325 pg/ml, 30-34 years ≥ 6.60 pg/ml, 35-39 years ≥ 7.05 pg/ml, 40-44 years ≥ 6.825 pg/ml, 45-49 years ≥ 7.075 pg/ml, 50-54 years ≥ 8.225 pg/ml, 55-59 years ≥ 11.15 pg/ml, 60-69 years ≥ 12.95 pg/ml. None of the p-values survived multiple testing. | | | |